Table 2.
Effectiveness outcomes in VISCO360-alone subgroup (n=11)
| Intraocular pressure (IOP) | |||
|---|---|---|---|
| Eyes available for analysis (n) | Mean IOP ± SD mmHg | Change from preoperative ± SD mmHg (95% CI) | Proportion of eyes with IOP reduction ≥20% |
| Preoperative (11/11) | 28.8±6.4 | N/A | N/A |
| Day 1 (11/11) | 14.0±7.1 | −14.8±10.5 (−17.0, −12.6) | 9/11 (82%, CI: 48%, 97%) |
| Month 1 (11/11) | 17.5±3.9 | −11.4±6.6 (−12.8, −10.0) | 9/11 (82%, CI: 48%, 97%) |
| Month 3 (9/11) | 17.2±2.1 | −11.6±8.2 (−13.5, −9.6) | 8/9 (89%, CI: 52%, 100%) |
| Month 6 (9/11) | 16.6±4.1 | −12.0±7.2 (−13.7, −10.3) | 6/9 (67%, CI: 30%, 93%) |
| Month 12 (11/11) | 14.5±3.6 | −14.3±6.9 (−15.7, −12.8) | 9/11 (82%, CI: 48%, 97%) |
| Eyes available for analysis (n) |
Mean number of IOP-lowering medications ± SD |
Change from preoperative ± SD (95% CI) | Fewer number of medications than preoperatively, N (%, 95% CI) |
| Preoperative (11/11) | 3.0±1.3 | N/A | N/A |
| Day 1 (11/11) | 0.0±0.0 | −3.0±1.3 (−3.3, −2.7) | 11/11 (100%) |
| Month 1 (11/11) | 0.2±0.4 | −2.8±1.4 (−3.1, −2.5) | 11/11 (100%) |
| Month 3 (9/11) | 0.6±0.9 | −2.3±1.3 (−2.6, −2.0) | 9/9 (100%) |
| Month 6 (9/11) | 1.1±1.2 | −1.9±1.5 (−2.2, −1.5) | 8/9 (89%, CI: 52%, 100%) |
| Month 12 (11/11) | 0.8±1.1 | −2.2±1.8 (−2.6, −1.8) | 10/11 (91%, CI: 58%, 99%) |
Notes: 95% CI=95% confidence interval per binomial distribution. The single standalone case in Group 2 is not included here because of the overall different treatment goals.